Massachusetts General, Beth Israel Deaconess hospitals testing in-home dementia care

Boston-based Massachusetts General Hospital and Beth Israel Deaconess Medical Center are among the hospitals and academic institutions testing artificial intelligence-powered tech solutions to help with in-home care of diseases such as Alzheimer's and dementia.

The new Massachusetts AI and Technology Center for Connected Care in Aging and Alzheimer's Disease, or MassAITC, at the University of Massachusetts Amherst distributed $1.7 million in National Institute on Aging funding Jan. 9 to its first seven pilot projects:

1. Testing a vocal biomarker platform for remote detection and monitoring of cognitive impairment (Massachusetts General Hospital and Sonde Health).

2. Sensor-guided psychopharmacology for Alzheimer's and related dementias (Belmont, Mass.-based McLean Hospital).

3. Early acute-illness detection for delirium and dementia (Beth Israel Deaconess Medical Center and Boston-based Northeastern University).

4. Smartphone blood pressure monitoring for healthy aging (University of California San Diego).

5. Developing real-world digital biomarkers from wearable sensors for Alzheimer's (UMass Amherst and VivoSense).

6. Detecting frailty at home through noninvasive, whole-room, body-heat sensing (UMass Amherst, Hebrew SeniorLife and Butlr Technologies).

7. Vascular aging using infrasonic hemodynography embedded into earbuds (MindMics).

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars